NCT01476332已完成1 期
A Single Dose (Part 1) and Multiple Dose (Part 2) Phase I, Double-blind, Placebo-controlled, Safety, Tolerability and Pharmacokinetic Study of 0.5% and 2.5% Cis-UCA Eye Drops in Adult Healthy Volunteers
Laurantis Pharma, Ltd.1 个研究点 分布在 1 个国家目标入组 37 人开始时间: 2011年11月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 37
- 试验地点
- 1
- 主要终点
- IER (Institute of Eye Research) grading scale evaluates bulbar conjunctival redness, lid redness and corneal staining and extent
研究概览
简要总结
The purpose of this two-part study is to evaluate safety, tolerability and pharmacokinetics of 0.5% and 2.5% cis-UCA eye drops in comparison to placebo in adult healthy volunteers.
详细描述
This is a Phase I single-centre, double-blind, placebo-controlled, single and multiple dose study to evaluate safety, ocular tolerability and pharmacokinetics of 0.5% and 2.5% cis-UCA eye drops in healthy volunteers for up to 15 days. After the single day dose (three times) on day 1 and the subsequent 7 (± 1) days wash-out period, a multidose phase with three times a day administration for 14 days will start
Primary objectives:
- Part 1: To evaluate the safety and ocular tolerability of 0.5% and 2.5% cis-UCA eye drops and placebo for cis-UCA eye drops when administered on a randomized eye three times during a single day, assessed up to 7 (± 1) days following dosing in healthy volunteers
- Part 2: To evaluate the safety and ocular tolerability of 0.5% and 2.5% cis-UCA eye drops and placebo for cis-UCA eye drops when administered on both eyes three times a day for 14 days, assessed up to 7 days following the last dosing in healthy volunteers
Secondary objectives:
- To evaluate single dose pharmacokinetics of 0.5% and 2.5% cis-UCA eye drops when administered on a randomized eye in adult healthy volunteers
- To evaluate the pharmacokinetics of 0.5% and 2.5% cis-UCA eye drops when administered on both eyes three times a day for 14 days in adult healthy volunteers
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Informed consent obtained prior to any screening procedure
- •Caucasian male or female subject
- •Age 18-65 y
- •Weight at least 45 kg
- •Corrected visual acuity > 20/25 in both eyes
- •Intraocular pressure < 21 mmHg, with a difference between eyes of < 4 mmHg
- •Ability to tolerate and self-administer vehicle eye drops
- •Normal slit lamp examination and dilated fundoscopic examination
- •Normal clinical laboratory profiles, defined as complete blood count, serum chemistry, and urinalysis values within the normal range
- •Willingness to abstain from concomitant use of ocular or systemic medication (excluding oral contraceptives, ibuprofen, paracetamol, calcium preparations and vitamins) from 2 weeks prior to the start of study dosing until study completion
- •Willingness to comply with study-related procedures
- •Negative urine pregnancy test (premenopausal female subject) at screening and use of adequate contraceptive measures throughout the study and 30 days after the last study medication dose
- •A premenopausal female subject should be either surgically sterile or using a reliable contraception method: intrauterine device; oral combination pill or hormonal contraception patch; or two of the following: intra-vaginal hormonal ring, oral contraceptive containing progestin only, spermicidal foam, condom, sterilization of male sexual partner (surgical vasectomy)
- •Subject with no current heterosexual relationship may be included according to the judgment of the Investigator
- •If menopause occurred 2 years ago at the minimum, no contraception is required for a female participant, nor pregnancy test
- •Reliable contraception for a male subject is concordant with above listed methods for females, as applicable
排除标准
- •History of ocular surgery, trauma, or chronic ocular disease
- •Current use of contact lenses or discontinuation of contact lens use within 2 weeks of the first dosing day
- •Any ocular abnormalities or ocular symptoms (defined as a non-zero score on assessment scales)
- •Use of ocular agents (including all types of eye drops) within the past month prior to the first dosing day or anticipated use of ocular agents during the study period
- •Use of systemic or inhaled nasal or pulmonary corticosteroids within the past month prior to the first dosing day
- •Use of systemic antihistamines within one week prior to the first dosing day
- •History or evidence of ocular infection, inflammation, blepharitis, or conjunctivitis within 2 months prior to the first dosing day; history of herpes simplex keratitis at any time
- •Current ocular allergy symptoms
- •Loss, donation, or removal of 400 ml or more of blood within 2 months prior to the first dosing day
- •Women who are pregnant or breastfeeding, or non-sterile or premenopausal women who refuse to use two proven methods of contraception during the study and for at least 30 days following the final dose of study drug
- •Participation in another clinical drug or device study within 2 months prior to the first dosing day
- •Current smoking
- •Current or history of drug or alcohol abuse
- •Known human immunodeficiency virus- or acquired immunodeficiency syndrome -related illness.
- •Allergy to cis-UCA, or any constituents of the cis-UCA eye drops (cis-urocanic acid, aqua, sodium chloride, polyvinyl alcohol, sodium hydroxide, and/or hydrochloric acid) or placebo for cis-UCA eye drops (aqua, sodium chloride, polyvinyl alcohol, sodium hydroxide, and/or hydrochloric acid)
- •Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, would affect the subject's ability to follow study-related procedures, or may interfere with the interpretation of study results and, in the Investigator's opinion, would make the subject inappropriate for entry into this study.
- •Doubtful availability to complete the study
研究组 & 干预措施
Group 1: Cis-UCA 0.5% eye drops
Experimental
干预措施: cis-urocanic acid 0,5% eye drops (Drug)
Group 2: Cis-UCA 2.5% eye drops
Experimental
干预措施: cis-urocanic acid 2.5% eye drops (Drug)
Group 3: Placebo for cis-UCA, eye drops
Placebo Comparator
干预措施: Placebo for cis-UCA, eye drops (Drug)
结局指标
主要结局
IER (Institute of Eye Research) grading scale evaluates bulbar conjunctival redness, lid redness and corneal staining and extent
时间窗: 36 days
次要结局
- Ocular comfort rating(36 days)
- Early Treatment Diabetic Retinopathy Study table, a visual acuity test(36 days)
- Anterior chamber cells and flare using SUN Working Group Grading Schemes(36 days)
- Ocular pressure(36 days)
- Schirmer's test(36 days)
研究者
研究点 (1)
Loading locations...
相似试验
终止
1 期
Study of OXB-102 (AXO-Lenti-PD) in Patients With Bilateral, Idiopathic Parkinson's DiseaseParkinson DiseaseNCT03720418Sio Gene Therapies6
终止
1 期
Study of MK-1972 in Human Immunodeficiency Virus (HIV)-1 Infected Participants Who Have Not Previously Received Antiretroviral Therapy (MK-1972-003)HIV-1 InfectionNCT01353898Merck Sharp & Dohme LLC12
已完成
1 期
A Study of the Safety and Pharmacokinetics of JNJ-38518168 in Japanese and Caucasian Male Participants and the Effect of JNJ-38518168 on the Blood Levels of MidazolamHealthy Male VolunteerNCT01442532Janssen Research & Development, LLC94
终止
1 期
A Study of ALN-AAT02 in Healthy Participants and Participants With ZZ Type Alpha-1 Antitrypsin Deficiency Liver DiseaseZZ Type Alpha-1 Antitrypsin Deficiency Liver DiseaseNCT03767829Alnylam Pharmaceuticals32
已完成
1 期
Pharmacokinetics - Pharmacodynamic Study of HT-2157 in Healthy Subjects and in Patients With Major Depressive DisorderHealthy Volunteers (Part 1)Major Depressive Disorder (Part 2)NCT01413932Dart NeuroScience, LLC26